Solasia Pharma K.K. — Investor Relations & Filings
Listed
Filings indexed
109
across all filing types
Latest filing
2026-05-15
Regulatory Filings
Country
JP
Japan
Solasia Pharma K.K. is a specialty pharmaceutical company focused on oncology. The company's business model involves in-licensing promising drug candidates to develop and commercialize them for patients in Asian markets. Its portfolio is centered on addressing unmet medical needs in both cancer treatment and supportive care, aiming to improve patients' quality of life. Key commercialized products include Sancuso® for chemotherapy-induced nausea and vomiting (CINV), DARVIAS® for peripheral T-cell lymphoma (PTCL), and episil® oral liquid, a medical device for pain associated with oral mucositis. The development pipeline includes candidates for treating chemotherapy-induced peripheral neuropathy (CIPN) and colorectal cancer.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Business Overview of Pipeline Products(First Quarter of the Fiscal Year Ending December 31, 2026) | 2026-05-15 | English | |
| Consolidated Financial Results for the Three Months Ended March 31, 2026 (Under IFRS) | 2026-05-15 | English | |
| 2026年12月期 第１四半期決算短信〔ＩＦＲＳ〕（連結） | 2026-05-15 | Japanese | |
| 確認書 | 2026-03-24 | Japanese | |
| 有価証券報告書－第18期(2025/01/01－2025/12/31) | 2026-03-24 | Japanese | |
| 2025年12月期 決算短信〔ＩＦＲＳ〕（連結） | 2026-02-13 | Japanese |
Browse filings by year
10 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
6 filings
| |||||
| 48042485 | Business Overview of Pipeline Products(First Quarter of the Fiscal Year Ending December 31, 2026) | 2026-05-15 | English | ||
| 48042484 | Consolidated Financial Results for the Three Months Ended March 31, 2026 (Under IFRS) | 2026-05-15 | English | ||
| 48198923 | 2026年12月期 第１四半期決算短信〔ＩＦＲＳ〕（連結） | 2026-05-15 | Japanese | ||
| 33017550 | 確認書 | 2026-03-24 | Japanese | ||
| 33017545 | 有価証券報告書－第18期(2025/01/01－2025/12/31) | 2026-03-24 | Japanese | ||
| 48198924 | 2025年12月期 決算短信〔ＩＦＲＳ〕（連結） | 2026-02-13 | Japanese | ||
|
2025
9 filings
| |||||
| 48198925 | 2025年度通期業績予想の修正に関するお知らせ | 2025-12-23 | Japanese | ||
| 48198926 | 2025年12月期 第３四半期決算短信〔ＩＦＲＳ〕（連結） | 2025-11-14 | Japanese | ||
| 7857964 | 確認書 | 2025-08-13 | Japanese | ||
| 7856974 | 半期報告書－第18期(2025/01/01－2025/12/31) | 2025-08-13 | Japanese | ||
| 48198927 | 2025年12月期 第２四半期（中間期）決算短信〔ＩＦＲＳ〕（連結） | 2025-08-13 | Japanese | ||
| 48198928 | 2025年12月期 第１四半期決算短信〔ＩＦＲＳ〕（連結） | 2025-05-14 | Japanese | ||
| 7269599 | 訂正有価証券届出書（組込方式） | 2025-03-31 | Japanese | ||
| 7269572 | 臨時報告書 | 2025-03-31 | Japanese | ||
| 7272475 | 訂正有価証券届出書（組込方式） | 2025-03-26 | Japanese | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
89bio, Inc.
Clinical-stage biopharma developing therapies for liver and…
|
ETNB | US | Manufacturing |
|
Aardvark Therapeutics, Inc.
Clinical-stage biopharma developing therapeutics for hunger…
|
AARD | US | Manufacturing |
|
Aarey Drugs & Pharmaceuticals Ltd
Manufactures APIs and chemical intermediates for global pha…
|
AAREYDRUGS | IN | Manufacturing |
|
Aarti Drugs Limited
Produces APIs, pharma intermediates, and specialty chemical…
|
AARTIDRUGS | IN | Manufacturing |
|
Aarti Pharmalabs Limited
Manufacturer of APIs, intermediates, and xanthines with glo…
|
AARTIPHARM | IN | Manufacturing |
|
AAYUSH WELLNESS LIMITED
Develops and markets herbal formulations, supplements, and …
|
539528 | IN | Manufacturing |
|
Ab&B Bio-Tech CO., LTD. JS
Biopharmaceutical company engaged in the R&D and commercial…
|
2627 | HK | Manufacturing |
|
Abbisko Cayman Limited
Clinical-stage biopharma focused on discovering and develop…
|
2256 | KY | Manufacturing |
|
Abbott India Ltd.
Provides pharmaceutical solutions in gastroenterology, card…
|
ABBOTINDIA | IN | Manufacturing |
|
ABBOTT LABORATORIES
Global healthcare company in medical devices, diagnostics, …
|
ABT | US | Manufacturing |
Solasia Pharma K.K. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/14027/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=14027 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=14027 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=14027 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 14027}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Solasia Pharma K.K. (id: 14027)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.